Commercial Services and Supplies
Company Overview of Pharmaceutical Research and Manufacturers of America
Pharmaceutical Research and Manufacturers of America (PhRMA) represents the research-based pharmaceutical and biotechnology companies. The company advocates for public policies that encourage discovery of new medicines for patients by pharmaceutical and biotechnology research companies. Its members consist of 3M Pharmaceuticals, Berlex Laboratories, Inc., GE Healthcare, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Wyeth, and Pfizer Inc. PhRMA was founded in 1958 and is based in Washington, DC.
950 F Street, NW
Washington, DC 20004
Founded in 1958
Key Executives for Pharmaceutical Research and Manufacturers of America
Chief Executive Officer and President
President of International Section
Senior Vice President of External Affairs
Senior Vice President of Communications
Compensation as of Fiscal Year 2016.
Pharmaceutical Research and Manufacturers of America Key Developments
Pharmaceutical Research and Manufacturers of America Announces Board Changes
Jan 9 17
The Pharmaceutical Research and Manufacturers of America (PhRMA) announced Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson, has been named chairman of PhRMA's board of directors. Duato formerly held the position of chairman-elect of the PhRMA board and succeeds George Scangos, who has stepped down as CEO of Biogen. Duato has served as worldwide chairman, pharmaceuticals at Johnson & Johnson since January 2011. During his 28-year career at Johnson & Johnson, Duato has worked across the company's pharmaceuticals and medical device business segments, held regional chairman roles and led local market businesses in a variety of countries and regions. As a dual citizen of Spain and the United States, he brings a unique international perspective to his work.
Pharmaceutical Research and Manufacturers of America Announces Management Changes
Nov 15 16
The Pharmaceutical Research and Manufacturers of America announced that Robert Zirkelbach has been named executive vice president of public affairs. Zirkelbach assumes the responsibilities of Josephine Martin, who announced her intent to pursue new opportunities.
Pharmaceutical Research and Manufacturers of America Highlights Continued Progress and Ongoing Efforts in the Research and Development of New Treatments
Nov 14 16
Pharmaceutical Research and Manufacturers of America (PhRMA) has highlighted continued progress and ongoing efforts in the research and development of new treatments for the more than 30 million Americans with diabetes and diabetes-related conditions. According to the report, there are now more than 170 medicines in development for type 1 diabetes, type 2 diabetes and related diseases, such as chronic kidney disease. The report highlights critical advancements in treatment that enable better adherence to medications and ultimately improved quality of health for patients. Diabetes is the seventh leading cause of death in the United States; in addition, 86 million Americans are considered pre-diabetic, which places them at higher risk to develop type 2 diabetes. The cost of diagnosed diabetes is $245 billion in the United States, and biopharmaceutical researchers are tirelessly working to find new lifesaving and life-changing treatments and cures to address this complex disease and the costs associated with it. For diabetes patients the continuous monitoring of blood sugar levels and numerous types of medications make the disease challenging to manage. The advancement of treatments and development of new medications supports better adherence by patients, which is crucial to avoiding hospitalizations. One study estimates improved adherence could avoid nearly 350,000 hospitalizations and nearly 700,000 emergency room visits each year in the United States, which results in reduced medical spending as great as $5,000 per patient annually. The report also acknowledges a positive trend in new diagnoses of diabetes, with the U.S. Centers for Disease Control and Prevention (CDC) citing a decrease in the rate of new diabetes cases diagnosed annually.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|